Ursodeoxycholic acid inhibits Ras mutations, wild-type Ras activation, and cyclooxygenase-2 expression in colon cancer

被引:0
|
作者
Khare, S
Cerda, S
Wali, RK
von Lintig, FC
Tretiakova, M
Joseph, L
Stoiber, D
Cohen, G
Nimmagadda, K
Hart, J
Sitrin, MD
Boss, GR
Bissonnette, M
机构
[1] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA
[2] Univ Chicago, Dept Med, Chicago, IL 60637 USA
[3] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
K-ras mutations occur frequently in colon cancer and contribute to autonomous growth. In the azoxymethane (AOM) model of colon cancer, in addition to K-ras mutations, we have shown that wild-type (WT) Ras can be activated by upstream pathways, including, e.g., signaling by ErbB receptors. Tumors with mutant or activated WT Ras had increased cyclooxygenase-2 (Cox-2) expression. We have also shown that ursodeoxycholic acid (UDCA) prevented AOM-induced colon cancer and suppressed Cox-2 induction. In this study, we examined the role of Ras in Cox-2 inhibition by UDCA. Rats were fed AIN-76A chow alone, or supplemented with 0.4% UDCA, and received 20 mg/kg AOM i.p. weekly x 2 weeks. At 40 weeks, rats were sacrificed, and tumors were harvested. K-ras mutations were assessed by primer-mediated RFLP, allele-specific oligonucleotide hybridization, and direct DNA sequencing. Ras was immunoprecipitated and defined as activated if [Ras - GTP/(Ras - GTP + Ras - GDP)] was >3 SD above normal colonocytes. Cox-2 mRNA was determined by reverse transcription-PCR, and protein expression was assessed by Western blotting and immuno-staining. In the AOM alone group, Ras was activated by mutations in 8 of 30 (27%) tumors, and WT Ras was activated in 7 of 30 (23%) tumors. UDCA significantly suppressed the incidence of tumors with mutant Ras (1 of 31, 3.2%; P < 0.05) and totally abolished the development of tumors with activated WT Ras (0 of 10; P < 0.05). In the AOM alone group, Cox-2 was up-regulated >50-fold in tumors with normal Ras activity and further enhanced in tumors with mutant or signaling-activated Ras. UDCA significantly inhibited Cox-2 protein and mRNA levels in tumors with normal Ras activity. In summary, we have shown for the first time that UDCA suppressed the development of tumors with Ras mutations and blocked activation of WT Ras. Furthermore, UDCA inhibited Cox-2 induction by Ras-dependent and -independent mechanisms.
引用
收藏
页码:3517 / 3523
页数:7
相关论文
共 50 条
  • [1] Ursodeoxycholic acid inhibits ras mutations, wild type Ras activation and cyclooxygenase-2 expression in colon cancer
    Khare, S
    Cerda, S
    Wali, R
    Von Lintig, FC
    Tretiakova, M
    Stoiber, D
    Cohen, G
    Nimmagadda, K
    Hart, J
    Sitrin, M
    Boss, GR
    Bissonnette, M
    [J]. GASTROENTEROLOGY, 2003, 124 (04) : A605 - A605
  • [2] Sulindac sulfone inhibits K-ras-dependent cyclooxygenase-2 expression in human colon cancer cells
    Taylor, MT
    Lawson, KR
    Ignatenko, NA
    Marek, SE
    Stringer, DE
    Skovan, BA
    Gerner, EW
    [J]. CANCER RESEARCH, 2000, 60 (23) : 6607 - 6610
  • [3] Chemopreventive ursodeoxycholic acid (UDCA) inhibits in vivo activation of ErbB2 and Ras by EGF in mouse colon
    Khare, S
    Little, N
    Cerda, S
    Mustafi, R
    Kumar, N
    Moore, C
    Cohen, G
    Joseph, L
    Fichera, A
    Bissonnette, M
    [J]. GASTROENTEROLOGY, 2004, 126 (04) : A26 - A26
  • [4] Regulation of RAS in colon cancer cells by chemopreventive ursodeoxycholic acid
    Khare, Sharad
    Baluch, Mehdi
    Holgren, Cory
    [J]. GASTROENTEROLOGY, 2006, 130 (04) : A181 - A182
  • [5] Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways
    Araki, Y
    Okamura, S
    Hussain, SP
    Nagashima, M
    He, PJ
    Shiseki, M
    Miura, K
    Harris, CC
    [J]. CANCER RESEARCH, 2003, 63 (03) : 728 - 734
  • [6] EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells
    Shimizu, Masahito
    Deguchi, Atsuko
    Joe, Andrew K.
    Mckoy, Judith F.
    Moriwaki, Hisataka
    Weinstein, I. Bernard
    [J]. JOURNAL OF EXPERIMENTAL THERAPEUTICS AND ONCOLOGY, 2005, 5 (01) : 69 - 78
  • [7] Controversies in the treatment of RAS wild-type metastatic colorectal cancer
    R. Vera
    M. Salgado
    M. J. Safont
    J. Gallego
    E. González
    E. Élez
    E. Aranda
    [J]. Clinical and Translational Oncology, 2021, 23 : 827 - 839
  • [8] Mutant and Wild-type Ras: Co-conspirators in Cancer
    Hayes, Tikvah K.
    Der, Channing J.
    [J]. CANCER DISCOVERY, 2013, 3 (01) : 24 - 26
  • [9] Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer
    Strickler, John H.
    Rushing, Christel N.
    Uronis, Hope E.
    Morse, Michael A.
    Niedzwiecki, Donna
    Blobe, Gerard C.
    Moyer, Ashley N.
    Bolch, Emily
    Webb, Renee
    Haley, Sherri
    Hatch, Ace J.
    Altomare, Ivy P.
    Sherrill, Gary B.
    Chang, David Z.
    Wells, James L.
    Hsu, S. David
    Jia, Jingquan
    Zafar, S. Yousuf
    Nixon, Andrew B.
    Hurwitz, Herbert I.
    [J]. ONCOLOGIST, 2021, 26 (06): : 465 - +
  • [10] The prognostic impact of sidedness in RAS wild-type colorectal cancer
    Tavares, N.
    Costa, A.
    Almeida, D.
    Meireles, S.
    Fernandes, C.
    Rey, C.
    Sarmento, C.
    Damasceno, M.
    [J]. ANNALS OF ONCOLOGY, 2018, 29